Davar et al. conducted a trial in 2021 to study the effect of fecal microbiota transplantation (FMT) in combination with anti-PD-1 therapy in 16 melanoma patients who were refractory to anti-PD-1 therapy and had progressive disease[87]. This evidence concerns the gene PDCD1 and melanoma.